Please login to the form below

Not currently logged in
Email:
Password:

Eisai/ UCL partnership grows

Eisai is to extend its partnership with University College London, a UK-based university with which the company has been collaborating with for more than 20 years

Eisai is to extend its partnership with University College London (UCL), a UK-based university with which the company has been collaborating with for more than 20 years.

The new phase will see the Eisai and UCL engage in joint research in neurodegenerative disease including biomarker research into neuroinflammation, neurovascular/mitochondria and proteostasis.

During the course of their partnership which began in 1990, Eisai and UCL established an Eisai research facility on the UCL campus and have forged strong co-operative ties through research activities that included the exchange of personnel.

Additionally Eisai said it plans to submit marketing authorisation applications to the regulatory authorities in the US and Europe for perampanel, a first-in-class, highly selective, non-competitive AMPA-type glutamate receptor antagonist that was created through collaborative with UCL research, to complement its marketed products which include Zonegran (zonisamide), Inovelon (rufinamide) and Zebinix (eslicarbazepine acetate).

26th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics